drugset / Trial / NCT00094549

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

NCT00094549 ↗

Phase 4 Completed 500 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The goals of this study are: A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. B. To assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients treated with olanzapine. C. To assess how olanzapine compares to divalproex.

Timeline

Start
2004-10
Primary completion
—
Completion
2006-12

Outcome

Met primary endpoint

paper patients significantly differed in YMRS baseline-to-endpoint total score change (p = .034; least squares [LS] mean: -9.4 and -7.4, respectively). PMID 19014751 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Divalproex Sodium Small molecule 500 mg —
Subject Divalproex Sodium Small molecule 2500 mg —
Subject Olanzapine Small molecule 5 mg —
Subject Olanzapine Small molecule 20 mg —

Indications